Clinical Trial Update: A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 study evaluating response-guided duration of combination therapy with GS-9451, Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) with and without …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• GS-9451 (GS-9451)
• Pegasys (pegylated interferon alfa-2a)
• Tegobuvir (Tegobuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED